Telo Genomics to flaunt breakthrough ICRA MRD Technology at a huge platform

Announcement

Telo Genomics Corp., a known face in prognostic and diagnostic innovation, is a leader ruling via its exclusive multifaceated telomere analytics, has declared that it will present an industry presentation at the Myeloma Canada MRD Testing Implementation Summit to light up on November 14-15. Telo’s groundbreaking Individual-cell risk assessment MRD technology (ICRA MRD) will ramp on this summit with confidence and potential. The laboratory director at Telo Genomics, Dr Yulia Shifrin, will be précising the Company’s excellent Minimal Residual Disease (MRD) technology at the summit.

Her presentation will demonstrate the primary clinical results describing the power of amalgamating Telo’s blood-related MRD workflow with the first-in-best MRD test, the potential of risk-profiling single cancer cells with the help of the TeloView® platform. This new ability expands MRD way excellently than disease quantification, serving prognostic insights, previously not considered with the conventional methods.

Early clinical findings in detail

The early clinical findings highlight that the myeloma patient group shows structural profiles and distinct genomic signatures at the single-cell stage that connect with the relapse risk and support their MRD status. This has added a new layer of prognostic smartness that holds the capability to precisely polish the clinical decision-making by enabling a quantifiable relapse-risk score rather than staying dependent on the threshold-related MRD, negatively and positively.

The Co-Founder of Telo Genomics, Dr Sabine Mai, said, “This summit has brought researchers, decision makers, patients and clinicians under one roof who can excel in the future diagnostics for the myeloma patient group. The recent MRD tools aim at calculating the disease presence. Our TeloView® platform has taken a crucial step ahead by driving and addressing the extreme, high-risk cells that will provoke relapse early. We see this as a future of MRD monitoring in various myeloma.”

Huge platform for Telo Genomics

Myeloma Canada is the only national and well-recognised charitable patient organisation open by and for Canadians affected by various myeloma. The organisation is committed to enhancing patient outcomes by elevating the reach to optimal care, spontaneously upgrading the research for better cure and prevention. The summit is engineered to contribute evidence-related decision-making for MRD equipping throughout academic and community clinical settings.

Telo Genomics ramped and utilised this huge platform brilliantly to showcase the best-in-class of its TeloView® platform. This impressive platform attracted every expert present at the summit.